denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
Program: Special-Interest Sessions
Session: ASH Research Collaborative Multiple Myeloma Network: Accelerating Research and Collaborative Clinical Care through Real-World Evidence Generation
Hematology Disease Topics & Pathways:
Research, Artificial intelligence (AI), Adult, Clinical Practice (Health Services and Quality), Elderly, Clinical Research, Health outcomes research, Bioinformatics, Patient-reported outcomes, Diseases, Real-world evidence, Registries, Lymphoid Malignancies, Technology and Procedures, Study Population, Human, Measurable Residual Disease
Session: ASH Research Collaborative Multiple Myeloma Network: Accelerating Research and Collaborative Clinical Care through Real-World Evidence Generation
Hematology Disease Topics & Pathways:
Research, Artificial intelligence (AI), Adult, Clinical Practice (Health Services and Quality), Elderly, Clinical Research, Health outcomes research, Bioinformatics, Patient-reported outcomes, Diseases, Real-world evidence, Registries, Lymphoid Malignancies, Technology and Procedures, Study Population, Human, Measurable Residual Disease
Saturday, December 7, 2024, 4:00 PM-5:30 PM
Disclosures: Zamagni: Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Menarini Stemline: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Honoraria, Membership on an entity's Board of Directors or advisory committees.